SAN DIEGO--(BUSINESS WIRE)-- Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) presented positive results today from a Phase 1 clinical trial of its Captisol-enabled (CE) Iohexol program at ASN ...
Amneal Pharmaceuticals announced that the U.S. FDA has approved its iohexol injection (300 mg Iodine/mL), the first generic version of GE Healthcare's Omnipaque, with plans to launch in the first ...
Hosted on MSN
Amneal gets FDA nod for Iohexol Injection
Amneal Pharmaceuticals (AMRX) has received approval from the U.S. FDA for its iohexol injection, which contains 300 mg of iodine per mL. This marks the introduction of the first generic version of GE ...
BRIDGEWATER, N.J., Nov. 13, 2025 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (“Amneal” or the “Company”) (Nasdaq: AMRX) today announced the U.S. Food and Drug Administration (FDA) has approved ...
BRIDGEWATER, N.J. - Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) announced Thursday that the U.S. Food and Drug Administration has approved its iohexol injection (300 mg Iodine/mL), the first generic ...
The recent lockdown in Shanghai, China, has had a serious impact on GE Healthcare's primary pharmaceutical manufacturing facility for iohexol (Omipaque, GE Healthcare) iodinated contrast media (ICM), ...
TOKYO--(BUSINESS WIRE)--Otsuka Pharmaceutical Co. Ltd. and its wholly-owned subsidiary Interpharma Praha, a.s. announced today that ORALTAG, a formulation of dry, dissolvable iohexol powder for oral ...
(MENAFN- GlobeNewsWire - Nasdaq) First-to-market complex injectable with expected launch in Q1 2026 BRIDGEWATER, N.J., Nov. 13, 2025 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (“Amneal” or ...
BRIDGEWATER, N.J., Nov. 13, 2025 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. ("Amneal" or the "Company") (Nasdaq: AMRX) today announced the U.S. Food and Drug Administration (FDA) has approved ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback